HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19 (2022)
Attributed to:
Phase 1 COVID-19 Immunity - National Core Study
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/imm.13450
PubMed Identifier: 35156709
Publication URI: http://europepmc.org/abstract/MED/35156709
Type: Journal Article/Review
Parent Publication: Immunology
Issue: 1
ISSN: 0019-2805